4-Oxypiperidine Ethers As Multiple Targeting Ligands at Histamine H Receptors and Cholinesterases

Overview

Journal ACS Chem Neurosci

Publisher American Chemical Society

Specialty Neurology

Date 2024 Mar 5

PMID 38440987

Authors

Beata Michalska

Marek Dziegielewski

Justyna Godyn

Tobias Werner

Marek Bajda

Tadeusz Karcz

Katarzyna Szczepanska

Holger Stark

Anna Wieckowska

Krzysztof Walczynski

Marek Staszewski

Affiliations

Soon will be listed here.

Abstract

This study examines the properties of a novel series of 4-oxypiperidines designed and synthesized as histamine HR antagonists/inverse agonists based on the structural modification of two lead compounds, viz., and . The products are intended to maintain a high affinity for HR while simultaneously inhibiting AChE or/and BuChE enzymes. Selected compounds were subjected to HR radioligand displacement and HR functional assays. Some of the compounds showed nanomolar affinity. The most promising compound in the naphthalene series was , which contained a benzyl moiety at position 1 of the piperidine ring and displayed 12.5 nM affinity at the HR and the highest inhibitory activity against AChE (IC = 1.537 μM). Eight compounds showed over 60% BuChE inhibition and hence were qualified for the determination of the IC value at BuChE; their values ranged from 0.559 to 2.655 μM. Therapy based on a multitarget-directed ligand combining HR antagonism with additional AChE/BuChE inhibitory properties might improve cognitive functions in multifactorial Alzheimer's disease.

References

Darras F, Pockes S, Huang G, Wehle S, Strasser A, Wittmann H . Synthesis, biological evaluation, and computational studies of Tri- and tetracyclic nitrogen-bridgehead compounds as potent dual-acting AChE inhibitors and hH3 receptor antagonists. ACS Chem Neurosci. 2014; 5(3):225-42. PMC: 3963125. DOI: 10.1021/cn4002126. View

Stark H, Sippl W, Ligneau X, Arrang J, Ganellin C, Schwartz J . Different antagonist binding properties of human and rat histamine H3 receptors. Bioorg Med Chem Lett. 2001; 11(7):951-4. DOI: 10.1016/s0960-894x(01)00090-7. View

Bembenek S, Keith J, Letavic M, Apodaca R, Barbier A, Dvorak L . Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling. Bioorg Med Chem. 2008; 16(6):2968-73. DOI: 10.1016/j.bmc.2007.12.048. View

Veber D, Johnson S, Cheng H, Smith B, Ward K, Kopple K . Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002; 45(12):2615-23. DOI: 10.1021/jm020017n. View

Pillot C, Ortiz J, Heron A, Ridray S, Schwartz J, Arrang J . Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat. J Neurosci. 2002; 22(16):7272-80. PMC: 6757889. DOI: 20026704. View

Maslowska-Lipowicz I, Walczynski K . Structure-activity relationships of new 1-substitutedmethyl-4-[5-(N-methyl-N-propylamino)pentyloxy]piperidines and selected 1-[(N-substituted-N-methyl)-3-propyloxy]-5-(N-methy-l-N-propyl)-pentanediamines as H3 -antagonists. Chem Biol Drug Des. 2013; 83(1):106-18. DOI: 10.1111/cbdd.12206. View

Fox G, Esbenshade T, Pan J, Radek R, Krueger K, Yao B . Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine.... J Pharmacol Exp Ther. 2004; 313(1):176-90. DOI: 10.1124/jpet.104.078402. View

Witkin J, Nelson D . Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther. 2004; 103(1):1-20. DOI: 10.1016/j.pharmthera.2004.05.001. View

Daina A, Michielin O, Zoete V . SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017; 7:42717. PMC: 5335600. DOI: 10.1038/srep42717. View

10.

Lazewska D, Jonczyk J, Bajda M, Szalaj N, Wieckowska A, Panek D . Cholinesterase inhibitory activity of chlorophenoxy derivatives-Histamine H3 receptor ligands. Bioorg Med Chem Lett. 2016; 26(16):4140-5. DOI: 10.1016/j.bmcl.2016.04.054. View

11.

Cho W, Maruff P, Connell J, Gargano C, Calder N, Doran S . Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. Psychopharmacology (Berl). 2011; 218(3):513-24. DOI: 10.1007/s00213-011-2344-y. View

12.

Petroianu G, Arafat K, Sasse B, Stark H . Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents. Pharmazie. 2006; 61(3):179-82. View

13.

Schlicker E, Fink K, Detzner M, Gothert M . Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. J Neural Transm Gen Sect. 1993; 93(1):1-10. DOI: 10.1007/BF01244933. View

14.

Ghose A, Viswanadhan V, Wendoloski J . A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem. 2000; 1(1):55-68. DOI: 10.1021/cc9800071. View

15.

Dauvilliers Y, Bassetti C, Lammers G, Arnulf I, Mayer G, Rodenbeck A . Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013; 12(11):1068-75. DOI: 10.1016/S1474-4422(13)70225-4. View

16.

Rapanelli M, Pittenger C . Histamine and histamine receptors in Tourette syndrome and other neuropsychiatric conditions. Neuropharmacology. 2015; 106:85-90. DOI: 10.1016/j.neuropharm.2015.08.019. View

17.

Clapham J, Kilpatrick G . Histamine H3 receptors modulate the release of [3H]-acetylcholine from slices of rat entorhinal cortex: evidence for the possible existence of H3 receptor subtypes. Br J Pharmacol. 1992; 107(4):919-23. PMC: 1907926. DOI: 10.1111/j.1476-5381.1992.tb13386.x. View

18.

Kilic B, Gulcan H, Aksakal F, Ercetin T, Oruklu N, Bagriacik E . Design and synthesis of some new carboxamide and propanamide derivatives bearing phenylpyridazine as a core ring and the investigation of their inhibitory potential on in-vitro acetylcholinesterase and butyrylcholinesterase. Bioorg Chem. 2018; 79:235-249. DOI: 10.1016/j.bioorg.2018.05.006. View

19.

Schlicker E, Fink K, Hinterthaner M, Gothert M . Inhibition of noradrenaline release in the rat brain cortex via presynaptic H3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1989; 340(6):633-8. DOI: 10.1007/BF00717738. View

20.

Khanfar M, Affini A, Lutsenko K, Nikolic K, Butini S, Stark H . Multiple Targeting Approaches on Histamine H3 Receptor Antagonists. Front Neurosci. 2016; 10:201. PMC: 4884744. DOI: 10.3389/fnins.2016.00201. View